CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Clevidipine

氯维地平 杂质对照品Clevidipine Impurities

31 个杂质条目31 impurity entries

本页汇总 氯维地平 的 31 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 31 impurity reference standards of Clevidipine. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 氯维地平(Clevidipine)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesStructural Analysis and Quantitative Determination of Clevidipine Butyrate Impurities Using an Advanced RP-HPLC Method
    Journal of chromatographic science · 2016 · Zhou Y et al.  ·  PMID 26489435  ·  DOI
  2. 分析方法Analytical MethodsDevelopment and validation of samples stabilization strategy and LC-MS/MS method for simultaneous determination of clevidipine and its primary metabolite in human plasma: Application to clinical pharmacokinetic study in Chinese healthy volunteers
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2020 · Zhang Y et al.  ·  PMID 33246284  ·  DOI
  3. 分析方法Analytical Methods[Simultaneous determination of clevidipine butyrate and its metabolite clevidipine acid in dog blood by liquid chromatography-tandem mass spectrometry]
    Yao xue xue bao = Acta pharmaceutica Sinica · 2015 · Wei HH et al.  ·  PMID 26837176
  4. 分析方法Analytical MethodsSimultaneous determination of clevidipine and its primary metabolite in dog plasma by liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic study
    Journal of pharmaceutical and biomedical analysis · 2014 · Zhou Y et al.  ·  PMID 25194342  ·  DOI
  5. 分析方法Analytical MethodsSimultaneous Quantitation of Clevidipine and Its Active Metabolite H152/81 in Human Whole Blood by LC-MS/MS: Application to Bioequivalence Study
    Frontiers in chemistry · 2022 · Li P et al.  ·  PMID 35464212  ·  DOI

氯维地平 —— 原料药与杂质对照品Clevidipine — drug substance & impurities

共 32 个条目(含原料药本体)32 items incl. the drug substance
Clevidipine structure
原料药 APIAPI
氯维地平Clevidipine
Clevidipine
CAS No.167221-71-8
Chemical FormulaC21H23Cl2NO6
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 1 structure
1
氯维地平杂质1Clevidipine Impurity 1
Clevidipine Impurity 1
CAS No.253597-19-2
Chemical FormulaC25H29Cl2NO8
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 3 structure
3
氯维地平杂质3Clevidipine Impurity 3
Clevidipine Impurity 3
CAS No.91189-59-2
Chemical FormulaC17H17Cl2NO4
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 4 structure
4
氯维地平杂质4Clevidipine Impurity 4
Clevidipine Impurity 4
CAS No.123853-39-4
Chemical FormulaC16H15Cl2NO4
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 5 structure
5
氯维地平杂质5Clevidipine Impurity 5
Clevidipine Impurity 5
CAS No.188649-48-1
Chemical FormulaC21H21Cl2NO6
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 6 structure
6
氯维地平杂质6Clevidipine Impurity 6
Clevidipine Impurity 6
CAS No.253597-20-5
Chemical FormulaC15H15Cl2NO2
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 7 structure
7
氯维地平杂质7Clevidipine Impurity 7
Clevidipine Impurity 7
CAS No.91854-02-3
Chemical FormulaC16H13Cl2NO4
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 8 structure
8
氯维地平杂质8Clevidipine Impurity 8
Clevidipine Impurity 8
CAS No.105383-68-4
Chemical FormulaC15H13Cl2NO2
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 9 structure
9
氯维地平杂质9Clevidipine Impurity 9
Clevidipine Impurity 9
CAS No.1898262-46-8
Chemical FormulaC15H14Cl2O3
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 10 structure
10
氯维地平杂质10Clevidipine Impurity 10
Clevidipine Impurity 10
CAS No.1801167-49-6
Chemical FormulaC15H14Cl2O3
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 12 structure
12
氯维地平杂质12Clevidipine Impurity 12
Clevidipine Impurity 12
CAS No.5402-53-9
Chemical FormulaC4H7ClO2
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 13 structure
13
氯维地平杂质13Clevidipine Impurity 13
Clevidipine Impurity 13
CAS No.175688-79-6
Chemical FormulaC21H19Cl2N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 16 structure
16
氯维地平杂质16Clevidipine Impurity 16
Clevidipine Impurity 16
CAS No.2458150-60-0
Chemical FormulaC21H23Cl2NO6
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 21 structure
21
氯维地平杂质21Clevidipine Impurity 21
Clevidipine Impurity 21
CAS No.2177293-82-0
Chemical FormulaC23H27Cl2NO6
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 22 structure
22
氯维地平杂质22Clevidipine Impurity 22
Clevidipine Impurity 22
CAS No.74073-26-0
Chemical FormulaC20H23Cl2NO4
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 24 (Mixture of E/Z-isomers) structure
24
氯维地平杂质24 (混合E/Z构型)Clevidipine Impurity 24 (Mixture of E/Z-isomers)
Clevidipine Impurity 24 (Mixture of E/Z-isomers)
CAS No.103295-97-2
Chemical FormulaC14H14Cl2O3
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 26 structure
26
氯维地平杂质26Clevidipine Impurity 26
Clevidipine Impurity 26
CAS No.1020718-27-7
Chemical FormulaC16H16Cl2O5
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 27 structure
27
氯维地平杂质27Clevidipine Impurity 27
Clevidipine Impurity 27
CAS No.1207068-15-2
Chemical FormulaC15H14Cl2O3
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 28 structure
28
氯维地平杂质28Clevidipine Impurity 28
Clevidipine Impurity 28
CAS No.1207068-16-3
Chemical FormulaC15H14Cl2O3
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 29 structure
29
氯维地平杂质29Clevidipine Impurity 29
Clevidipine Impurity 29
CAS No.1207068-17-4
Chemical FormulaC15H14Cl2O3
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 34 structure
34
氯维地平杂质34Clevidipine Impurity 34
Clevidipine Impurity 34
CAS No.294194-13-1
Chemical FormulaC19H23ClO6
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 36 structure
36
氯维地平杂质36Clevidipine Impurity 36
Clevidipine Impurity 36
CAS No.91854-03-4
Chemical FormulaC15H11Cl2NO4
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 37 structure
37
氯维地平杂质37Clevidipine Impurity 37
Clevidipine Impurity 37
CAS No.175688-78-5
Chemical FormulaC20H20Cl2N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 39 structure
39
氯维地平杂质39Clevidipine Impurity 39
Clevidipine Impurity 39
CAS No.167221-70-7
Chemical FormulaC20H21Cl2NO6
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 40 (Mixture of E/Z-isomers) structure
40
氯维地平杂质40 (混合E/Z构型)Clevidipine Impurity 40 (Mixture of E/Z-isomers)
Clevidipine Impurity 40 (Mixture of E/Z-isomers)
CAS No.43107-08-0
Chemical FormulaC7H10N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 41 structure
41
氯维地平杂质41Clevidipine Impurity 41
Clevidipine Impurity 41
CAS No.1346550-30-8
Chemical FormulaC15H16Cl2O3
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 42 structure
42
氯维地平杂质42Clevidipine Impurity 42
Clevidipine Impurity 42
CAS No.404373-25-7
Chemical FormulaC11H8Cl2O3
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 43 structure
43
氯维地平杂质43Clevidipine Impurity 43
Clevidipine Impurity 43
CAS No.404373-64-4
Chemical FormulaC10H8Cl2O
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 45 structure
45
氯维地平杂质45Clevidipine Impurity 45
Clevidipine Impurity 45
CAS No.88977-32-6
Chemical FormulaC7H10N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 47 structure
47
氯维地平杂质47Clevidipine Impurity 47
Clevidipine Impurity 47
CAS No.193539-61-6
Chemical FormulaC7H10N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 49 structure
49
氯维地平杂质49Clevidipine Impurity 49
Clevidipine Impurity 49
CAS No.6361-23-5
Chemical FormulaC7H4Cl2O
Purity>95%询价On request
10mg25mg50mg100mg
Clevidipine Impurity 55 structure
55
氯维地平杂质55Clevidipine Impurity 55
Clevidipine Impurity 55
CAS No.68064-68-6
Chemical FormulaC14H14Cl2O3
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

氯维地平 —— 研究文献与合成路线Clevidipine — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 氯维地平 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Clevidipine. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Structural Analysis and Quantitative Determination of Clevidipine Butyrate Impurities Using an Advanced RP-HPLC Method
    Zhou Y, Zhou F, Yan F, et al. · Journal of chromatographic science · 2016

合成与制备工艺专利Synthesis & process patents

  1. PREPARATION OF CLEVIDIPINE BUTYRATE
    SOUZA FABIO, PAN MING · 公开号 WO2011127599WO2011127599 · 2011
  2. PREPARATION OF CLEVIDIPINE BUTYRATE RING THE SAME
    SOUZA FABIO E S, PAN MING · 公开号 CA2701087CA2701087 · 2011
  3. New preparation method of key intermediate of clevidipine butyrate
    GUOHUA CHEN, XIUZHI CAO, MINGLIANG ZHANG · 公开号 CN101602710CN101602710 · 2009

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

氯维地平 杂质谱研究要点Clevidipine — impurity profiling notes

下面这些是拿到 氯维地平 的 32 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 32 impurity entries for Clevidipine, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances